How Difficult and Expensive Is Coverage with Evidence Development? - Perry Bridger

↳ This is a section part of Moment: CRT 2015 Technology & Innovation - Session III: What Are the Challenges and Potential Solutions to Meeting Clinical Data Requirements for Premarket Approval (PMA), Post-Market Surveillance and Reimbursement?

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$15.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

How Difficult and Expensive Is Coverage with Evidence Development? presented by Perry Bridger at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$15.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physicians with an interest in Cardiovascular Innovations

Session Name: Session III: What Are the Challenges and Potential Solutions to Meeting Clinical Data Requirements for Premarket Approval (PMA), Post-Market Surveillance and Reimbursement?

Track: Technology & Innovation

Learning Objectives

Updates in the latest Cardiovascular Innovations

Other Components in this Moment

Overview

Too Costly, Too Slow: The Current PMA Requirements - Keith D. Dawkins, MD

Post-Market Studies: Large Investment, Little Return - Neal E. Fearnot, PhD

Alternatives to Randomized Premarket Studies - Laura Mauri, MD

Balancing Pre and Post-Market Data Requirements: Different Scenarios - Dorothy B. Abel, BSBME

Use of Quality Initiative Registries to Meet Regulatory and Reimbursement Requirements - William S. Weintraub, MD

CMS Participation: Will There Be a Problem with Reimbursement If Less Data Is Available Premarket? - Tamara Syrek Jensen, JD

How Difficult and Expensive Is Coverage with Evidence Development? - Perry Bridger

Problems Will Arise: Is the US Public Ready to Accept Change? - Aaron V. Kaplan, MD